Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001641172-25-013033
Filing Date
2025-05-30
Accepted
2025-05-30 16:10:49
Documents
18
Period of Report
2025-05-30

Document Format Files

Seq Description Document Type Size
1 PRE 14A formpre14a.htm   iXBRL PRE 14A 654390
2 GRAPHIC proxy_001.jpg GRAPHIC 251193
3 GRAPHIC proxy_002.jpg GRAPHIC 371328
  Complete submission text file 0001641172-25-013033.txt   2886443

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE gtbp-20241231.xsd EX-101.SCH 7205
5 XBRL DEFINITION FILE gtbp-20241231_def.xml EX-101.DEF 12029
6 XBRL LABEL FILE gtbp-20241231_lab.xml EX-101.LAB 70637
7 XBRL PRESENTATION FILE gtbp-20241231_pre.xml EX-101.PRE 44197
20 EXTRACTED XBRL INSTANCE DOCUMENT formpre14a_htm.xml XML 142948
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-40023 | Film No.: 251011002
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)